Literature DB >> 35464287

The 11th revision of the International Statistical Classification of Disease and Related Health Problems and Cholangiocarcinoma.

Shijie Cai1, Shivan Sivakumar2.   

Abstract

Entities:  

Year:  2022        PMID： 35464287      PMCID： PMC9023819          DOI： 10.21037/hbsn-22-69

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  14 in total

1.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.

Authors:  S A Khan; B R Davidson; R Goldin; S P Pereira; W M C Rosenberg; S D Taylor-Robinson; A V Thillainayagam; H C Thomas; M R Thursz; H Wasan
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

Review 2.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

3.  Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Authors:  Milind Javle; Maeve Lowery; Rachna T Shroff; Karl Heinz Weiss; Christoph Springfeld; Mitesh J Borad; Ramesh K Ramanathan; Lipika Goyal; Saeed Sadeghi; Teresa Macarulla; Anthony El-Khoueiry; Robin Kate Kelley; Ivan Borbath; Su Pin Choo; Do-Youn Oh; Philip A Philip; Li-Tzong Chen; Thanyanan Reungwetwattana; Eric Van Cutsem; Kun-Huei Yeh; Kristen Ciombor; Richard S Finn; Anuradha Patel; Suman Sen; Dale Porter; Randi Isaacs; Andrew X Zhu; Ghassan K Abou-Alfa; Tanios Bekaii-Saab
Journal:  J Clin Oncol       Date:  2017-11-28       Impact factor: 44.544

4.  Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.

Authors:  John N Primrose; Richard P Fox; Daniel H Palmer; Hassan Z Malik; Raj Prasad; Darius Mirza; Alan Anthony; Pippa Corrie; Stephen Falk; Meg Finch-Jones; Harpreet Wasan; Paul Ross; Lucy Wall; Jonathan Wadsley; Jeff T R Evans; Deborah Stocken; Raaj Praseedom; Yuk Ting Ma; Brian Davidson; John P Neoptolemos; Tim Iveson; James Raftery; Shihua Zhu; David Cunningham; O James Garden; Clive Stubbs; Juan W Valle; John Bridgewater
Journal:  Lancet Oncol       Date:  2019-03-25       Impact factor: 41.316

5.  Cholangiocarcinoma miscoding in hepatobiliary centres.

Authors:  Shaun Selvadurai; Kulbir Mann; Sanjena Mithra; John Bridgewater; Hassan Malik; Shahid A Khan
Journal:  Eur J Surg Oncol       Date:  2020-10-01       Impact factor: 4.424

6.  Effectiveness of repeat hepatic resection for patients with recurrent intrahepatic cholangiocarcinoma: Factors associated with long-term outcomes.

Authors:  Anfeng Si; Jun Li; Xianglei Xing; Zhengqing Lei; Yong Xia; Zhenlin Yan; Kui Wang; Lehua Shi; Feng Shen
Journal:  Surgery       Date:  2016-12-16       Impact factor: 3.982

Review 7.  Emerging molecular therapeutic targets for cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  J Hepatol       Date:  2017-04-05       Impact factor: 25.083

8.  Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.

Authors:  Vivek Subbiah; Ulrik Lassen; Elena Élez; Antoine Italiano; Giuseppe Curigliano; Milind Javle; Filippo de Braud; Gerald W Prager; Richard Greil; Alexander Stein; Angelica Fasolo; Jan H M Schellens; Patrick Y Wen; Kert Viele; Aislyn D Boran; Eduard Gasal; Paul Burgess; Palanichamy Ilankumaran; Zev A Wainberg
Journal:  Lancet Oncol       Date:  2020-08-17       Impact factor: 41.316

9.  Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Authors:  Ghassan K Abou-Alfa; Teresa Macarulla; Milind M Javle; Robin K Kelley; Sam J Lubner; Jorge Adeva; James M Cleary; Daniel V Catenacci; Mitesh J Borad; John Bridgewater; William P Harris; Adrian G Murphy; Do-Youn Oh; Jonathan Whisenant; Maeve A Lowery; Lipika Goyal; Rachna T Shroff; Anthony B El-Khoueiry; Bin Fan; Bin Wu; Christina X Chamberlain; Liewen Jiang; Camelia Gliser; Shuchi S Pandya; Juan W Valle; Andrew X Zhu
Journal:  Lancet Oncol       Date:  2020-05-13       Impact factor: 41.316

10.  Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.

Authors:  Angela Lamarca; Daniel H Palmer; Harpreet Singh Wasan; Paul J Ross; Yuk Ting Ma; Arvind Arora; Stephen Falk; Roopinder Gillmore; Jonathan Wadsley; Kinnari Patel; Alan Anthoney; Anthony Maraveyas; Tim Iveson; Justin S Waters; Claire Hobbs; Safia Barber; W David Ryder; John Ramage; Linda M Davies; John A Bridgewater; Juan W Valle
Journal:  Lancet Oncol       Date:  2021-03-30       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.